Monensin prevents terminal glycosylation of the N- and O-linked oligosaccharides of the HLA-DR-associated invariant chain and inhibits its dissociation from the alpha-beta chain complex

Proc Natl Acad Sci U S A. 1984 Mar;81(5):1287-91. doi: 10.1073/pnas.81.5.1287.

Abstract

In B-lymphoblastoid cells, the HLA-DR-associated invariant chain is processed to a form containing O-linked as well as N-linked oligosaccharides. After neuraminidase treatment, the O-linked carbohydrate is susceptible to digestion with an endoglycosidase (endo-beta-N-acetylgalactosaminidase) that cleaves glycans with the structure Gal(beta 1----3)-GalNAc-Ser/Thr, and sialic acid can be added back to this core oligosaccharide by specific sialyltransferases. Treatment of cells with the sodium ionophore monensin markedly affects the post-translational processing of the invariant chain, although that of associated alpha and beta chains is minimally affected. Only a small portion of the N-linked carbohydrate on the invariant chain is processed to an endoglycosidase-H-resistant form. The sialic acid residues normally found on the O-linked glycans are not added, but at least the first residue, GalNAc, is added. In addition to the changes in glycosylation, an intracellular accumulation of HLA-DR antigens also occurs in monensin-treated cells. The accumulation of HLA-DR antigens and the overall slower turnover rates of the alpha, beta, and invariant polypeptides observed after monensin treatment probably reflects the build-up of newly synthesized proteins in Golgi apparatus-derived vacuoles coupled with a decrease in normal degradation in lysosomes.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • B-Lymphocytes / immunology
  • Carbohydrate Conformation
  • Carbohydrate Sequence
  • Cell Line
  • Furans / pharmacology*
  • HLA-DR Antigens
  • Hexosaminidases
  • Histocompatibility Antigens Class II / genetics*
  • Histocompatibility Antigens Class II / isolation & purification
  • Humans
  • Macromolecular Substances
  • Monensin / pharmacology*
  • Neuraminidase
  • Oligosaccharides / genetics*
  • Protein Processing, Post-Translational / drug effects*
  • Radioimmunoassay
  • alpha-N-Acetylgalactosaminidase

Substances

  • Furans
  • HLA-DR Antigens
  • Histocompatibility Antigens Class II
  • Macromolecular Substances
  • Oligosaccharides
  • Monensin
  • Hexosaminidases
  • Neuraminidase
  • NAGA protein, human
  • alpha-N-Acetylgalactosaminidase